Acasti Pharma Inc. (TSXV:ACS)

Healthcare

Acasti Pharma Inc develops prescription drugs for treating cardiovascular diseases.

The pharmaceutical firm develops, researches, and manufactures cardiometabolic drugs using omega-3 fatty acids from krill oil.

The company claims that omegra-3 have been clinically tested to lower the levels of triglycerides in patients suffering from hypertriglyceridemia. Since its inception in 2008, the company focuses on discovering new lines of treatment for cardiometabolic diseases.

The pharma firm’s is listed on the TSX and NASDAQ under the symbol ‘ACST’.

The biopharmaceutical company previously developed a cardiovascular drug, CaPre to treat hypertriglyceridemia. It is a chronic condition that affects around 1/3rd population in the United States, reportedly. The company claims to have identified increased demand for an effective and safe drug to deal with lipids and fats in the blood, which leads to cardiovascular diseases and strokes.

Its core product, CaPre, is presently a development Phase 3 clinical program.

CaPre is derived from a krill oil mixture that consists of various omega-3 fatty acids– polyunsaturated fatty acids (PUFAs), docosahexaenoic (DHA) acid, eicosapentaenoic (EPA) acid.

The firm says that the DHA and EPA are good for human health as they promote a healthy heart, improve visual functions and brain health. These acids are also aid in reducing inflammation and blood triglycerides. The PUFAs present in the CaPre drug reach the small intestine where it is absorbed rapidly and transformed to a complex fat molecule required for transport in the bloodstream.

The company claims that its product is distinct as since it is made using krill oil that consists of phospholipids. It also believes that DHA and EPA are better transported by phospholipids in krill oil rather than the same acids contained in fish oil or other omega-3 drugs as the latter system requires additional digestion prior to getting transported in the bloodstream.

The company is engaged in product development and distribution partnerships in the United States and other major global markets regarding its signature candidate, CaPre.

On May 7, 2021, the pharma company announced its intention to acquire Grace Therapeutics, a biopharmaceutical company developing drug delivery technologies to treat rare orphan diseases.

According to the agreement, Acasti will acquire the entire therapeutic pipeline of three unique clinical-stage assets and multiple pre-clinical stage drugs along with a portfolio of 40 granted and pending patents in different jurisdictions in the world.

As of 2021, the pharmaceutical firm holds numerous patents, of which certain are approved and pending in the United States, Japan, China, Australia, and Taiwan.

Contact Information

company address "3009 boul. de la Concorde E. Suite 102 Laval, Qu├ębec H7E 2B5"

company phone450 686-4555

company email[email protected]

company websitehttps://www.acastipharma.com/en

Similar Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK